Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Beam Therapeutics (BEAM) Assets Average: 2020-2025

Historic Assets Average for Beam Therapeutics (BEAM) over the last 6 years, with Sep 2025 value amounting to $1.4 billion.

  • Beam Therapeutics' Assets Average rose 11.08% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 11.08%. This contributed to the annual value of $1.3 billion for FY2024, which is 8.49% down from last year.
  • Latest data reveals that Beam Therapeutics reported Assets Average of $1.4 billion as of Q3 2025, which was down 5.45% from $1.4 billion recorded in Q2 2025.
  • Beam Therapeutics' Assets Average's 5-year high stood at $1.5 billion during Q1 2022, with a 5-year trough of $572.5 million in Q1 2021.
  • Over the past 3 years, Beam Therapeutics' median Assets Average value was $1.3 billion (recorded in 2023), while the average stood at $1.3 billion.
  • As far as peak fluctuations go, Beam Therapeutics' Assets Average soared by 260.44% in 2021, and later dropped by 17.27% in 2024.
  • Beam Therapeutics' Assets Average (Quarterly) stood at $1.3 billion in 2021, then rose by 2.32% to $1.3 billion in 2022, then increased by 2.17% to $1.4 billion in 2023, then fell by 17.27% to $1.1 billion in 2024, then rose by 11.08% to $1.4 billion in 2025.
  • Its last three reported values are $1.4 billion in Q3 2025, $1.4 billion for Q2 2025, and $1.3 billion during Q1 2025.